Whitehawk Therapeutics to Present at the Jefferies 2026 Global Healthcare Conference
Rhea-AI Summary
Whitehawk Therapeutics (Nasdaq: WHWK) announced that President and CEO Dave Lennon, PhD, will present at the Jefferies 2026 Global Healthcare Conference in New York City on Thursday, June 4 at 8:10 AM ET.
A live and replay webcast will be available on the company’s IR website for ~30 days.
Positive
- None.
Negative
- None.
News Market Reaction – WHWK
In the May 29 session, WHWK declined 1.26%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 21 | ADC pipeline expansion | Positive | +4.4% | Expanded access to CPT113 linker-payload for up to five ADC programs. |
| May 20 | Conference participation | Neutral | +1.5% | CEO fireside chat at TD Cowen oncology innovation summit. |
| May 15 | Conference participation | Neutral | -7.8% | Announcement of virtual fireside chat at Stifel oncology forum. |
| May 13 | Private placement financing | Positive | +25.8% | Approximately $87.5M private placement to extend cash runway into 2H 2028. |
| May 07 | Quarterly earnings update | Negative | -5.1% | Q1 2026 results with higher R&D spend and a $22.2M net loss. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent WHWK news has mostly seen price moves align with the tone of announcements, with one notable divergence on a prior conference participation headline.
Over recent months, Whitehawk reported several catalysts. An ADC option deal on May 21, 2026 and a private placement of about $87.5 million on May 13, 2026 both coincided with positive price reactions. Earlier, Q1 2026 results on May 7, 2026 saw a decline as the company highlighted a net loss of $22.2 million. Multiple conference participation notices, including events on May 19 and May 27, 2026, produced mixed but generally modest moves. Today’s Jefferies conference appearance fits this sequence of ongoing visibility-building events.
Key Terms
antibody drug conjugate medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
A live webcast of the fireside chat can be accessed by visiting the Whitehawk Therapeutics IR website and will be available for replay for approximately 30 days following the event.
About Whitehawk Therapeutics
Whitehawk Therapeutics is a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved cancer treatments. Whitehawk's advanced three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers. These assets are in-licensed from
Contact:
IR@whitehawktx.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/whitehawk-therapeutics-to-present-at-the-jefferies-2026-global-healthcare-conference-302784951.html
SOURCE Whitehawk Therapeutics, Inc.